Terremoto Biosciences Appoints Charles Baum, M.D., Ph.D., as Chief Executive Officer
2024年7月25日 - 9:00PM
ビジネスワイヤ(英語)
Terremoto Biosciences, a biotechnology company developing first-
and best-in-class targeted therapeutics, today announced the
appointment of Charles Baum, M.D., Ph.D., as Chief Executive
Officer. Dr. Baum succeeds Peter Thompson, M.D., who will continue
to serve as Terremoto’s Board chairperson.
“Chuck has a legacy of successful leadership in precision
therapeutics, most recently at Mirati Therapeutics, where under his
guidance, the company was transformed and went on to create
compelling pipeline value that led to an acquisition by Bristol
Meyers Squibb for up to $5.8 billion,” said Thompson. "I’m honored
to hand the reins over to him as the leader of Terremoto. His
extensive experience in drug development, and proven track record
in advancing high-impact medicines, will be instrumental as we
continue to develop treatments that promise superior therapeutic
benefit to patients."
Terremoto is harnessing the power of an expanded covalent
alphabet to create highly targeted therapeutics for a variety of
devastating and severe diseases. The company is applying its unique
capabilities to develop best-in-class therapies against known drug
targets and first-in-class medicines against high value previously
undrugged targets in oncology and beyond.
"Terremoto’s compelling science and innovative approach to
developing and advancing groundbreaking medicines creates an
unmatched opportunity to fundamentally change the treatment
paradigm for people with devastating diseases,” said Dr. Baum. “It
is a privilege to join the dynamic team at Terremoto as we are well
positioned to discover and develop novel treatments that will have
a significant impact on people with a variety of significant unmet
needs.”
Prior to his tenure at Mirati, Dr. Baum was deeply involved in
oncology development at Pfizer, where he was responsible for the
development of several major drugs, including Inlyta®, Xalkori®,
Ibrance® and Sutent®. While at Schering Plough, he contributed to
the development of Temodar® for the treatment of patients with
glioblastoma. His career also includes significant academic and
clinical positions at prestigious institutions such as Stanford and
Emory Universities. Dr. Baum holds an M.D. and a Ph.D. from
Washington University School of Medicine and completed his
post-graduate training at Stanford University. He has authored more
than 50 peer-reviewed publications and holds several patents in the
field of medical sciences.
About Terremoto Biosciences
Terremoto Biosciences is a drug discovery and development
company creating highly targeted, small molecule medicines with
unmatched selectivity, potency and efficacy designed to deliver
superior therapeutic benefit to patients. Terremoto is supported by
leading investors including OrbiMed, Third Rock Ventures, EcoR1
Capital, Novo Holdings and Cormorant Capital. More information is
available at www.terremotobio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240725098139/en/
Media Jake Robison Inizio Evoke Comms
jake.robison@inizioevoke.com